Adjuvant trastuzumab for breast cancer: We need to ensure that equity exists for access to effective and expensive treatments

Por Dent, Rebecca, Clemons, Mark
Publicado em 2005

End-of-life care in Canada

Por Simmons, Christine, Clemons, Mark
Publicado em 2006

Helping expectations become reality for dying cancer patients

Por Simmons, Christine, Clemons, Mark
Publicado em 2006

Do we need more hospices?

Por Clemons, Mark J, Kong, Wing May
Publicado em 1993

A simple approach for eliminating spam

Por Mazzarello, Sasha, Fralick, Michael, Clemons, Mark
Publicado no Curr Oncol (2016)

Recent developments in bisphosphonates for patients with metastatic breast cancer

Por Gainford, Mary C, Dranitsaris, George, Clemons, Mark
Publicado em 2005

The Mayan Doomsday’s effect on survival outcomes in clinical trials

Por Wheatley-Price, Paul, Hutton, Brian, Clemons, Mark
Publicado em 2012

Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

Por Ng, Terry L., Hutton, Brian, Clemons, Mark
Publicado no Oncologist (2015)

Treatment of locally advanced breast cancer

Por Verma, Sunil, Clemons, Mark, Fitzgerald, Barbara, Freedman, Orit
Publicado em 2004

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?

Por Russell, Kent, Clemons, Mark, Costa, Luis, Addison, Christina L.
Publicado no J Bone Oncol (2012)

Approach to inflammatory breast cancer

Por Molckovsky, Andrea, Fitzgerald, Barbara, Freedman, Orit, Heisey, Ruth, Clemons, Mark
Publicado em 2009

Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review

Por Jacobs, Carmel, Hutton, Brian, Ng, Terry, Shorr, Risa, Clemons, Mark
Publicado no Oncologist (2015)

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting

Por Jacobs, Carmel, Amir, Eitan, Paterson, Alexander, Zhu, Xiaofu, Clemons, Mark
Publicado no J Bone Oncol (2015)

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting

Por Zhu, Xiaofu, Amir, Eitan, Singh, Gurmit, Clemons, Mark, Addison, Christina
Publicado no J Bone Oncol (2014)

Renal cell carcinoma bone metastases: clinical advances

Por Sahi, Chakshu, Knox, Jennifer J., Clemons, Mark, Joshua, Anthony M., Broom, Reuben
Publicado em 2010

Incidence and consequences of bone metastases in lung cancer patients

Por Kuchuk, Michael, Addison, Christina L., Clemons, Mark, Kuchuk, Iryna, Wheatley-Price, Paul
Publicado no J Bone Oncol (2013)

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases

Por Simos, Demetrios, Addison, Christina L., Kuchuk, Iryna, Hutton, Brian, Mazzarello, Sasha, Clemons, Mark
Publicado no J Clin Med (2013)

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists

Por Kuchuk, Iryna, Mazzarello, Sasha, Butterfield, Kevin, Appleton, Anthony, Addison, Christina L., Clemons, Mark
Publicado no J Bone Oncol (2013)

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer

Por Hutton, Brian, Addison, Christina L., Campbell, Kaitryn, Fergusson, Dean, Mazarello, Sasha, Clemons, Mark
Publicado no J Bone Oncol (2013)

Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines

Por Fralick, Michael, Ray, Monali, Fung, Christina, Booth, Christopher M., Mallick, Ranjeeta, Clemons, Mark J.
Publicado em 2013